A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC) (2012)
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma (2012)
A Phase II Trial of Erlotinib plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy. (2012)
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology, drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.